US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
META
$728.08
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
SPCX
$158.96
▲+0.00%
JNJ
$256.03
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
META
$728.08
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
SPCX
$158.96
▲+0.00%
JNJ
$256.03
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
MorphoSys AG - American Depositary Shares
(NQ:
MOR
)
18.96
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about MorphoSys AG - American Depositary Shares
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
↗
July 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
July 07, 2021
Gainers Dare Bioscience (NASDAQ:DARE) shares increased by 51.97% to $2.31 during Wednesday's pre-market session. The market value of their outstanding shares is at $...
Via
Benzinga
MorphoSys Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Constellation Pharmaceuticals
July 01, 2021
MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino...
From
MorphoSys AG
Via
AccessWire
MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
June 25, 2021
- If approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the European Union - The positive opinion from the CHMP is...
From
MorphoSys AG
Via
AccessWire
Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
June 25, 2021
From
Incyte
Via
Business Wire
MorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation Pharmaceuticals
June 16, 2021
PLANEGG, GERMANY / ACCESSWIRE / June 16, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) ("MorphoSys") today announced that it is commencing a cash tender offer to purchase all outstanding shares of...
From
MorphoSys AG
Via
AccessWire
Benzinga's Top Ratings Upgrades, Downgrades For June 11, 2021
↗
June 11, 2021
Upgrades Barclays upgraded the previous rating for Ventas Inc (NYSE:VTR) from Equal-Weight to Overweight. In the first quarter, Ventas showed an EPS of $0.72, compared to...
Via
Benzinga
10 Biggest Price Target Changes For Friday
↗
June 11, 2021
Barclays lowered Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) price target from $302 to $285. Vertex Pharmaceuticals shares fell 13.3% to $187.88 in pre-market trading....
Via
Benzinga
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
↗
June 07, 2021
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,...
Via
Benzinga
MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
June 04, 2021
Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc., a...
From
MorphoSys AG
Via
AccessWire
Why MorphoSys Stock Sank This Week
↗
June 03, 2021
Investors weren't happy about the drugmaker's wheeling and dealing.
Via
The Motley Fool
Why Constellation Pharmaceuticals Stock Was Crushing It This Week
↗
June 03, 2021
The small drugmaker is being acquired by MorphoSys.
Via
The Motley Fool
The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout
↗
June 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 2) BioCryst Pharmaceuticals,...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2021
↗
June 03, 2021
Upgrades According to B of A Securities, the prior rating for Bloom Energy Corp (NYSE:BE) was changed from Underperform to Neutral. For the first quarter, Bloom Energy had...
Via
Benzinga
Mid-Afternoon Market Update: Constellation Pharmaceuticals Surges Following Acquisition News; Protalix BioTherapeutics Shares Slide
↗
June 02, 2021
Toward the end of trading Wednesday, the Dow traded up 0.05% to 34,594.18 while the NASDAQ fell 0.16% to 13,715.08. The S&P also rose, gaining 0.02% to 4,202.76. The U.S. has...
Via
Benzinga
Topics
Stocks
66 Biggest Movers From Yesterday
↗
June 03, 2021
Gainers AMC Entertainment Holdings, Inc. (NYSE: AMC) surged 95.2% to close at $62.55 on Wednesday amid renewed interest from retail investors. AMC Entertainment shares jumped...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
June 02, 2021
Gainers Constellation (NASDAQ:CNST) shares rose 67.19% to $33.84 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume of 19.5...
Via
Benzinga
Mid-Day Market Update: Crude Oil Rises 1%; iRhythm Technologies Shares Plunge
↗
June 02, 2021
`Midway through trading Wednesday, the Dow traded up 0.33% to 34,689.77 while the NASDAQ rose 0.16% to 13,758.43. The S&P also rose, gaining 0.30% to 4,214.55. The U.S. has...
Via
Benzinga
Topics
Stocks
Why Constellation Pharmaceuticals Stock Is Skyrocketing Today
↗
June 02, 2021
The company is being acquired by MorphoSys.
Via
The Motley Fool
40 Stocks Moving In Wednesday's Mid-Day Session
↗
June 02, 2021
Gainers BriaCell Therapeutics Corp. (NASDAQ: BCTX) shares jumped 147.3% to $7.86 after the company provided an update on the overall survival (OS) data on its previously...
Via
Benzinga
Mid-Morning Market Update: Markets Open Higher; Advance Auto Parts Profit Tops Estimates
↗
June 02, 2021
Following the market opening Wednesday, the Dow traded up 0.26% to 34,665.01 while the NASDAQ rose 0.15% to 13,757.62. The S&P also rose, gaining 0.23% to 4,211.85. The U.S....
Via
Benzinga
Topics
Stocks
Stocks That Hit 52-Week Lows On Wednesday
↗
June 02, 2021
Before 10 a.m. ET on Wednesday, 8 companies hit new 52-week lows. Highlights: Dun & Bradstreet Hldgs (NYSE:DNB) was the biggest company by market cap to set a new 52-...
Via
Benzinga
Constellation Pharma Rockets On Word Of $1.7 Billion MorphoSys Takeover
↗
June 02, 2021
MorphoSys announced its $1.7 billion plan to acquire cancer treatment biotech Constellation on Wednesday and CNST stock rocketed to a four-month high.
Via
Investor's Business Daily
Why Constellation Pharmaceuticals Is Soaring Today
↗
June 02, 2021
Constellation Pharmaceuticals Inc (NASDAQ: CNST) is trading higher Wednesday morning after an announcement that MorphoSys AG (NASDAQ: MOR) will acquire the company. What Happened...
Via
Benzinga
MorphoSys to Acquire Constellation Pharma at $34/Share; Enters $2B Strategic Funding with Royalty Pharma
↗
June 02, 2021
MorphoSys AG (NASDAQ: MOR) has agreed to acquire Constellation Pharmaceuticals Inc (NASDAQ: CNST) for $34/share in cash, representing a total equity value of...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
June 02, 2021
Gainers Constellation (NASDAQ:CNST) shares moved upwards by 66.55% to $33.71 during Wednesday's pre-market session. The market value of their outstanding shares is at...
Via
Benzinga
MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma
June 02, 2021
MUNICH, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / June 2, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys"), announces today that it has entered into a definitive agreement with Constellation...
From
MorphoSys AG
Via
AccessWire
Topics
Regulatory Compliance
MorphoSys to Acquire Constellation Pharmaceuticals
June 02, 2021
From
MorphoSys AG
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2021
↗
May 24, 2021
Upgrades Seaport Global upgraded the previous rating for Public Service Enterprise Group Inc (NYSE:PEG) from Neutral to Buy. Public Service Enterprise earned $1.28 in the...
Via
Benzinga
MorphoSys To Participate in UBS Global Healthcare Conference
May 21, 2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that Jean-Paul Kress, M.D., the company's Chief Executive Officer, will participate in a...
From
MorphoSys AG
Via
AccessWire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
